Level One Evidence Proves Premenopausal Patients within the Ultra-Low Subset of Agendia’s MammaPrint Low Risk Result Can Safely Forgo Chemotherapy
Retrieved on:
Tuesday, December 6, 2022
Oncology, Health, Consumer, Women, Genetics, Biotechnology, Consensus, Ultra, Physician, Prognosis, Theatre, Molecular Endocrinology, Recurrence, OFS, Breast cancer, JAMA Oncology, American Journal of Clinical Oncology, FACS, Journal of Clinical Oncology, National Cancer Institute, Gene expression profiling, Patient, Mayo Clinic, Metastasis, Cancer, Toxicity, Oncology, Cardozo, Biology, Consensus decision-making, Blueprint, Neoplasm, FDA, Disease, Breast, Woman, Quality of life, Black, Surgeon, Role, Behavior, Journal, Genomics, Marie Cassidy, Risk, Growth, Cancer survivor, Fertility, DRS, Medical imaging, Birth control, Dietary supplement, Medical device, MD, MammaPrint
Agendias MammaPrint is the only FDA-cleared test that can identify an Ultra-Low risk tumor as a separate risk level from the Low-risk group and therefore inform distinct treatment plans.
Key Points:
- Agendias MammaPrint is the only FDA-cleared test that can identify an Ultra-Low risk tumor as a separate risk level from the Low-risk group and therefore inform distinct treatment plans.
- Without the level of precision MammaPrint offers, these tumors risk may be underestimated or overtreated.
- While Agendias original MINDACT data found a small 3-4% chemotherapy benefit in premenopausal women with a MammaPrint Low risk result, according to a panel of breast cancer experts including Drs.
- MammaPrint is a 70-gene prognostic test that, along with other clinicopathologic factors, determines a specific patients breast cancer recurrence risk.